吉西他滨联合奥沙利铂治疗老年晚期非小细胞肺癌的临床研究  

A clinical study on the combination of gemcitabine and oxaliplatin in treatment of elderly patients with advanced non-small cell lung cancer

作　　者：王海燕[1] 侯梅[1] 王泽阳[1] 陈萍[1] 徐聂[1] 赵振华[1] 

机构地区：[1]四川大学华西医院肿瘤中心,四川成都610041

出　　处：《西部医学》2009年第6期907-908,共2页Medical Journal of West China

摘　　要：目的观察吉西他滨联合奥沙利铂治疗老年晚期非小细胞肺癌的疗效及毒副反应。方法对31例老年晚期非小细胞肺癌,给予吉西他滨1000mg/m2静脉滴注,第1、8天;奥沙利铂130mg/m2静脉滴注,第1天、21天为1个周期,至少2个周期。结果部分缓解(partial response,PR)12例,缓解率38.7%,稳定(stable disease,SD)10例,疾病控制率(PR+SD)71.0%;进展(progressive disease,PD)9例,疾病进展率29.0%,中位生存期为11.2个月。主要毒副反应是骨髓抑制,多数为Ⅰ度血小板减少。结论吉西他滨与奥沙利铂联合治疗老年晚期非小细胞肺癌有较好的疗效,耐受性好。Objective To valuate the efficacy and toxicity of the combination of gemcitabine and oxaliplatin in treatment of elderly patients with advanced non-small cell lung cancer （NSCLC）. Methods Thirty-one elderly patients with locally advarlced （stage ⅢB） or metastatic （stage Ⅳ） NSCLC were enrolled into our study. The subjects were treated with gemcitabine 1000 mg/m^2 on day 1 and day 8, oxaliplatin 130 mg/m^2 on day 1, administered in 21-day cycle. Each subject was given for two courses at least. Results The overall response rate was 38. 7% （12 partial response）. 10 cases were stable and 9 progressive. Median survival duration was 11.2 months. The main toxicity was myelosuppression, most of which were Grade Ⅰ-Ⅲ leukopenia or thrombocytopenia. Conclusions The combination of gemcitabine and oxaliplatin is effective and well-tolerated in treatment of elderly patients with advanced NSCLC.

关 键 词：吉西他滨 奥沙利铂 化疗 晚期非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]